RIPE-KG · Version 1.1.0 · Resource

ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4

https://w3id.org/ripe/ripe-kg/research-integrity-assessment/RIPEA5FB7D7932E6BCAF4

Subject	Predicate	Object
`ripekg:evaluation/RIPEA5FB7D7932E6BCAF4`	`tido:contributesTo`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:evidence-aggregation/RIPEA5FB7D7932E6BCAF4`	`tido:contributesTo`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:integrity-assessment-hypothesis/RIPEA5FB7D7932E6BCAF4-human-1-1`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:integrity-assessment-hypothesis/RIPEA5FB7D7932E6BCAF4-human-1-2`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:integrity-assessment-hypothesis/RIPEA5FB7D7932E6BCAF4-human-1-3`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:integrity-assessment-hypothesis/RIPEA5FB7D7932E6BCAF4-human-2-2`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:integrity-assessment-hypothesis/RIPEA5FB7D7932E6BCAF4-human-overall`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:integrity-assessment-hypothesis/RIPEA5FB7D7932E6BCAF4-inspectai-1-1`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:integrity-assessment-hypothesis/RIPEA5FB7D7932E6BCAF4-inspectai-1-2`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:integrity-assessment-hypothesis/RIPEA5FB7D7932E6BCAF4-inspectai-1-3`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:integrity-assessment-hypothesis/RIPEA5FB7D7932E6BCAF4-inspectai-2-2`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:publication-details/RIPEA5FB7D7932E6BCAF4`Use of recombinant human folliclestimulating hormone in the treatment of male factor infertility	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:registry-evidence/RIPEA5FB7D7932E6BCAF4`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`rdf:type`	`rdfs:Resource`
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`rdf:type`	`owl:Thing`
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`rdf:type`	`ripe:ResearchIntegrityAssessment`Research integrity assessment
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`rdf:type`	`tido:Case`
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`ripe:assesses`	`ripekg:work/RIPEW3F5F59749D227951`Use of recombinant human folliclestimulating hormone in the treatment of male factor infertility
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`tido:investigates`	`ripekg:integrity-assessment-question/post-publication-notices/1.0.0`1.2. Does the study have an associated expression of concern or other relevant post-publication notice?
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`tido:investigates`	`ripekg:integrity-assessment-question/post-publication-notices/1.0.0`post-publication notices
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`tido:investigates`	`ripekg:integrity-assessment-question/research-team-related-concerns/1.0.0`1.3. Do other studies by the research team highlight causes for concern?
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`tido:investigates`	`ripekg:integrity-assessment-question/research-team-related-concerns/1.0.0`research-team-related concerns
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`tido:investigates`	`ripekg:integrity-assessment-question/retraction-status/1.0.0`1.1. Does the study have an associated retraction?
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`tido:investigates`	`ripekg:integrity-assessment-question/retraction-status/1.0.0`retraction status
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`tido:investigates`	`ripekg:integrity-assessment-question/study-registration/1.0.0`2.2. Are there concerns relating to the timing or absence of study registration?
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`tido:investigates`	`ripekg:integrity-assessment-question/study-registration/1.0.0`study registration
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`tido:investigates`	`ripekg:overall-integrity-assessment-question/1.0.0`What is the overall integrity assessment of the study?
`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`	`tido:investigates`	`ripekg:overall-integrity-assessment-question/1.0.0`overall integrity assessment
`ripekg:retraction-notice/17286`Expression of phosphodiesterase type 5A in human spermatozoa and influence of its inhibition on motility and functional sperm parameters	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`
`ripekg:study-design-evidence/RIPEA5FB7D7932E6BCAF4`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA5FB7D7932E6BCAF4`